

Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte-defined Peptide Derived from the Tumor Antigen MAGE-3

By Danila Valmori,* Uzi Gileadi,[‡] Catherine Servis,[§] P. Rod Dunbar,[‡] Jean-Charles Cerottini,* Pedro Romero,* Vincenzo Cerundolo,[‡] and Frédéric Lévy*

From the *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, CH-1066 Epalinges, Switzerland; the [‡]Institute of Molecular Medicine, Nuffield Department of Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, United Kingdom; and the [§]Institute of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland

Summary

We have analyzed the presentation of human histocompatibility leukocyte antigen-A*0201-associated tumor peptide antigen MAGE-3₂₇₁₋₂₇₉ by melanoma cells. We show that specific cytotoxic T lymphocyte (CTL)-recognizing cells transfected with a minigene encoding the preprocessed fragment MAGE-3₂₇₁₋₂₇₉ failed to recognize cells expressing the full length MAGE-3 protein. Digestion of synthetic peptides extended at the NH₂ or COOH terminus of MAGE-3₂₇₁₋₂₇₉ with purified human proteasome revealed that the generation of the COOH terminus of the antigenic peptide was impaired. Surprisingly, addition of lactacystin to purified proteasome, though partially inhibitory, resulted in the generation of the antigenic peptide. Furthermore, treatment of melanoma cells expressing the MAGE-3 protein with lactacystin resulted in efficient lysis by MAGE-3₂₇₁₋₂₇₉-specific CTL. We therefore postulate that the generation of antigenic peptides by the proteasome in cells can be modulated by the selective inhibition of certain of its enzymatic activities.

Key words: HLA class I molecule • antigen processing • melanoma cells • ubiquitin • mass spectrometry

The proteasome is a central, nonlysosomal protease localized in the nuclei and cytosol of eukaryotic cells. It has been implicated in the catabolism of numerous intracellular proteins, including transcription factors and regulatory proteins as well as misfolded proteins (1–3). It is composed of a 20S core onto which a cap, formed by at least 15 different protein subunits, associates in an ATP-dependent manner, resulting in a 26S proteasome particle (4). The 26S proteasome has been shown to degrade ubiquitylated protein substrates (3). A second cap, formed by the heterodimeric PA-28 α/β (REG α/β) has also been described (5, 6). This cap increases the catalytic activity of the 20S proteasome toward oligopeptides and, in certain cases, modulates the cleavage activity of the proteasome, at least in vitro (7). This form of the proteasome does not degrade ubiquitylated substrates.

The 20S core proteasome is composed of 14 different subunits arranged in 4 heptameric rings denoted as $\alpha_7\beta_7\beta_7\alpha_7$ (8, 9). The catalytic centers of the proteasome are localized

in the interior of the β subunits. Studies on the degradation of short fluorogenic peptides by purified proteasome in vitro have demonstrated the presence of at least five different enzymatic activities: a tryptic-like activity, cleaving after basic residues; a chymotryptic-like activity, cleaving after hydrophobic amino acids; a peptidylglutamylpeptide hydrolyzing (PGPH)¹ activity, cleaving after acidic residues; a “branched chain amino acid–preferring” (BrAAP) activity; and a “small neutral amino acid–preferring” (SNAAP) activity (10).

The participation of the proteasome in the generation of antigenic peptides presented by MHC class I molecules has

¹Abbreviations used in this paper: AMC, 7-amido-4-methylcoumarin; BrAAP, branched chain amino acid–preferring; ER, endoplasmic reticulum; E/T, effector-to-target cell ratio; GFP, green fluorescence protein; ha, hemagglutinin epitope; LLnL, *N*-acetyl-Leu-Leu-norleucinal; MALDI-TOF, matrix assisted laser desorption ionization-time of flight; PGPH, peptidylglutamylpeptide hydrolyzing; rec. v.v., recombinant vaccinia virus; SNAAP, small neutral amino acid–preferring; TAP, transporters associated with antigen presentation; Ub, ubiquitin; UPR, ubiquitin/protein/reference.

D. Valmori and U. Gileadi contributed equally to this work.

been well documented (11–13). After their generation, antigenic peptides are transported across the membrane of the endoplasmic reticulum (ER) by the transporters associated with antigen presentation (TAP). In the ER, newly synthesized MHC class I heavy chain, β_2 -microglobulin, and peptide form a trimolecular complex that is then transported to the cell surface (14). Purification and biochemical characterization of peptides naturally associated with defined MHC class I alleles led to the discovery that these peptides are of relatively homogenous length (8–10 amino acids) and carry conserved amino acid residues at certain positions. These residues, defined as anchor residues, were shown to form direct contacts with the MHC molecule. Based on this information, the prediction of putative antigenic peptides for defined MHC class I proteins has become possible.

MAGE-3 belongs to the human *MAGE* multigene family, is characterized by its tumor-restricted expression, and gives rise to several antigenic peptides presented by different MHC class I molecules (15–17). *MAGE-3* antigenic peptides have therefore become attractive candidates for the study of antitumor responses by CTL. In an attempt to identify antigenic peptides, a series of 9-mer peptide sequences derived from the *MAGE-3* protein and carrying anchor residues for HLA-A*0201 were chemically synthesized and tested for binding to HLA-A*0201. Among the *MAGE-3*-derived peptides binding to HLA-A*0201, one peptide, *MAGE-3*_{271–279}, was able to induce a specific CTL response *in vitro* when added to a culture of PBL from an HLA-A*0201⁺ healthy individual (17). Subsequently, peptide *MAGE-3*_{271–279} was used to derive specific CTL using PBL from melanoma patients (18). Surprisingly, these CTL were able to lyse HLA-A*0201⁺ melanoma cells pulsed with exogenous peptides but were unable to recognize melanoma cells expressing the *MAGE-3* protein endogenously. To elucidate this discrepancy, we have investigated the processing of the *MAGE-3* gene product.

Here we show that the lack of presentation of peptide *MAGE-3*_{271–279} by HLA-A*0201⁺ cells is caused by the inaccurate cleavage of the *MAGE-3* protein during its processing. Cells were tested for recognition by *MAGE-3*_{271–279}-specific CTL following intracellular expression of a minigene-encoded *MAGE-3*_{271–279} peptide extended either at the NH₂ or COOH terminus. In contrast to cells expressing the NH₂-terminally extended peptide precursor, cells expressing the COOH-terminally extended peptide precursor were not recognized by specific CTL. Mass spectrometry analysis of the corresponding synthetic peptide precursors incubated with purified human proteasome demonstrated that the antigenic peptide could be generated from the NH₂-terminally extended precursor but not from the COOH-terminally extended precursor. Surprisingly, addition of a specific proteasome inhibitor, lactacystin, restored the generation of the antigenic peptide from the COOH-terminally extended precursor. Analysis of the enzymatic activity of the proteasome in the presence of the proteasome inhibitor supported this discrepancy. Finally, treatment of HLA-A*0201⁺ melanoma cells expressing

MAGE-3 with lactacystin or another proteasome inhibitor, *N*-acetyl-Leu-Leu-norleucinal (LLnL), restored the presentation of *MAGE-3*_{271–279}. Implication of these findings on the modulatory effect of proteasome inhibitor on the generation of peptides presented by HLA class I is discussed.

Materials and Methods

Cell Lines. The human melanoma cell lines NA8-MEL (provided by Dr. F. Jotereau, Institut National de la Santé et de la Recherche Médicale, Nantes, France) and SK23-MEL were cultured in RPMI medium (GIBCO BRL) supplemented with 10% FCS, antibiotics, and 20 mM NaHepes (pH 7.3). The CTL line LAU 198 NS (normal stimulation) specific for peptide *MAGE-3*_{271–279} was established by stimulating CD8⁺-enriched cells from a LAU 198 melanoma patient with peptide-pulsed, autologous PBL as described (18). The CTL line was restimulated weekly with irradiated (3,000 rads) autologous PBL. Before irradiation, PBL were incubated for 2 h at 37°C in serum-free medium (X-VIVO 10; Bio-Whittaker) in the presence of the synthetic peptide *MAGE-3*_{271–279} (1 μ g/ml) and 3 μ g/ml human β_2 -microglobulin (Sigma Chemical Co.) and then washed extensively to remove unattached peptide. The CTL clone 3C5 used in Fig. 7 was isolated as described previously (19). In brief, PBL were stained with tetramers of HLA-A*0201- β_2 -microglobulin containing the peptide *MAGE-3*_{271–279}. After cell sorting by FACS® (Becton Dickinson), positive cells were cloned in the presence of irradiated PBL, 5 μ g/ml PHA, and 50 U/ml IL-2 in human serum containing IMDM. The human lymphoblastoid cell lines T2 and LCL721.45 were used as targets in ⁵¹Cr release assay. These cells were cultured in DMEM (GIBCO BRL) supplemented with 10% FCS, 0.55 mM arginine, 0.24 mM asparagine, and 1.5 mM glutamine. The TNF- α -sensitive cell line WEHI-164 clone 13 was maintained in RPMI medium (GIBCO BRL) supplemented with 10% FCS, 0.55 mM arginine, 0.24 mM asparagine, and 1.5 mM glutamine.

Construction of Plasmids and Ubiquitin/Protein/Reference (UPR) Technique. All plasmid constructs described in this study were based on the plasmid pS65T-C1 (Clontech). This vector carries, under the control of the cytomegalovirus immediate early promoter, a mutated version of the green fluorescence protein (GFP), resulting in brighter fluorescence. The stop codon of the GFP moiety has been replaced by a multicloning site allowing COOH-terminal fusions to GFP. A fragment encoding yeast ubiquitin (Ub) carrying a lysine₄₈ to arginine mutation (to preclude that the COOH-terminal Ub moiety could serve as a ubiquitylation/degradation signal) and an influenza hemagglutinin epitope (ha) recognized by a monoclonal antibody was obtained by PCR, using the plasmid pRc/dUb-Met- β gal as template (20). This PCR fragment was digested with KpnI and SmaI and inserted in frame between the KpnI and SmaI sites present in the multicloning site of pS65T-C1, resulting in the vector pGFP_{Aval}/Ub expressing the fusion GFP-ha-Ub. The ha epitope is located between the GFP and Ub moieties. The plasmid pGFP_{Aval}/Ub was further digested with XhoI and EcoRI, blunted using Klenow PolII, and religated, thereby eliminating the Aval site between GFP and Ub and rendering the site Aval at the 3' end of Ub unique. This latter construct, termed pGFP/Ub, served as vector for all constructs described below.

Construct I (Fig. 1) was obtained by PCR amplification of a fragment encoding the tumor antigen *MAGE-3* (a gift from T. Boon, Ludwig Institute for Cancer Research, Brussels, Belgium). This PCR fragment was digested with SacII and Aval and inserted in frame between the SacII and Aval sites of pGFP/Ub, re-

sulting in the plasmid pGFP/Ub-MAGE-3₁₋₃₁₄. The protein MAGE-3 includes the natural NH₂-terminal methionine. Constructs II, III, and IV were obtained by annealing complementary synthetic oligonucleotides encoding the MAGE-3-derived peptide fragments MAGE-3₂₇₁₋₂₇₉, MAGE-3₂₅₆₋₂₇₉, and MAGE-3₂₇₁₋₂₈₅, respectively. The oligonucleotides were designed so as to reconstitute the SacII site at the 5' end and the Aval site at the 3' end of the fragment and included a stop codon immediately upstream of the Aval site. Upon annealing, the fragments were inserted between the SacII-Aval sites of pGFP/Ub, resulting in the plasmids pGFP/Ub-MAGE-3₂₇₁₋₂₇₉ (Fig. 1, construct II), pGFP/Ub-MAGE-3₂₅₆₋₂₇₉ (construct III), and pGFP/Ub-MAGE-3₂₇₁₋₂₈₅ (construct IV). The sequences of the critical regions of all constructs were confirmed by DNA sequencing.

Transfection and Metabolic Labeling. Cells were transiently transfected using the Lipofectamine reagent (GIBCO BRL) according to the manufacturer's protocol. For metabolic labeling, 3×10^6 cells were transfected with 4 μ g plasmid DNA. After 8 h, an equal volume of DMEM containing 10% FCS was added to the cells. After a further 12-h incubation at 37°C, the culture medium was replaced with 1 ml DMEM lacking methionine and




Figure 1. (A) UPR constructs. The plasmid pGFP/Ub-MAGE-3₁₋₃₁₄ encodes a tripartite fusion protein in which ubiquitin (Ub) is sandwiched between the reference protein GFP_{ha} and the full length protein MAGE-3 (construct I). During or shortly after the translation of this fusion, the GFP_{ha}-Ub moiety is cleaved at the last residue of Ub by a Ub-specific protease, resulting in equimolar amounts of the reference protein GFP_{ha}-Ub and the protein MAGE-3. The plasmid pGFP/Ub-MAGE-3₂₇₁₋₂₇₉ (construct II) encodes the reference protein GFP_{ha}-Ub and a fragment of MAGE-3 corresponding to the antigenic peptide associated with HLA-A*0201. The plasmid pGFP/Ub-MAGE-3₂₅₆₋₂₇₉ (construct III) encodes the reference protein GFP_{ha}-Ub and a fragment of MAGE-3 corresponding to a 15-amino acid NH₂-terminal extension of the antigenic peptide MAGE-3₂₇₁₋₂₇₉. The plasmid pGFP/Ub-MAGE-3₂₇₁₋₂₈₅ (construct IV) encodes the reference protein GFP_{ha}-Ub and a fragment of MAGE-3 corresponding to a six-amino acid COOH-terminal extension of MAGE-3₂₇₁₋₂₇₉. The residue methionine at the NH₂ terminus of the protein GFP results from the translation of the initiation codon ATG. The term ha denotes a peptide sequence derived from the influenza hemagglutinin that is recognized by a specific antibody. The segment corresponding to the antigenic peptide in each construct is indicated as a white box. (B) Synthetic peptides corresponding to the NH₂-terminal (MAGE-3₂₅₆₋₂₇₉) and the COOH-terminal (MAGE-3₂₇₁₋₂₈₅) extensions of the antigenic 9-mer are described in one-letter code together with their molecular masses in daltons (Da). The antigenic peptide sequence is boxed.

cysteine (ICN Biomedicals, Inc.), and the cells were incubated for 1 h at 37°C. Cells were labeled for 90 min at 37°C in the presence of 200 μ Ci of [³⁵S]Express (New England Nuclear). The cells were then lysed in 1 ml lysis buffer (1% Triton X-100, 0.15 M NaCl, 5 mM EDTA, 20 mM Tris-HCl [pH 7.3], and 0.2 mg/ml phenylmethylsulfonyl fluoride) and maintained on ice. The lysate was cleared by centrifugation at 12,000 *g* for 10 min. The volumes of supernatant were adjusted to contain equal amount of 10% TCA-insoluble, ³⁵S-labeled material and immunoprecipitated using a mixture of a saturating amount of a monoclonal antibody anti-ha epitope (Berkeley Antibody Co.) and a monoclonal antibody against MAGE-3 (21; a gift from G. Spagnoli, University of Basel, Basel, Switzerland). The samples were incubated with rotary shaking at 4°C for 30 min, followed by the addition of 20 μ l protein G-Sepharose and another 30-min incubation at 4°C. The immunoprecipitate was washed three times in lysis buffer containing 0.1% SDS, resuspended in 20 μ l SDS-sample buffer (100 mM Tris-HCl, pH 8.8; 1.2 M sucrose; 0.01% bromophenol blue; 2% SDS; and 90 mM dithiothreitol), and boiled at 100°C for 3 min. The samples were subjected to SDS-12% PAGE followed by autoradiography.

TNF- α Release Assay. Cells were transfected using the same protocol as for the metabolic labeling with the following modifications: 10⁴ cells were transfected in 96-well, round bottom microtiter plates with 200 ng plasmid DNA and 1 μ l Lipofectamine in a final volume of 100 μ l DMEM. After 6 h at 37°C, 100 μ l DMEM containing 10% FCS was added to each well, and the cells were maintained at 37°C for another 14 h. At this point, the transfected cells were tested for their ability to stimulate the release of TNF- α by the MAGE-3₂₇₁₋₂₇₉-specific CTL line. In brief, CTLs were added at the appropriate effector-to-target cell ratio (E/T) in 100 μ l of IMDM supplemented with 10% human serum and 20 U/ml human rIL-2 (Glaxo Wellcome) provided by Dr. M. Nabholz (Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland). After a 24-h incubation at 37°C, supernatants were collected and the TNF- α content was determined in a functional assay using WEHI-164 clone 13 cells (22) as described (23).

Proteasome Purification. Proteasome was purified from human outdated blood by affinity chromatography using the monoclonal antibody MCP 21 (European Collection of Animal Cell Cultures) immobilized on CnBr-activated Sepharose (6 mg antibody/mg Sepharose; 24). ~150 ml blood was washed five times with cold PBS, and the cells were pelleted at 2,000 *g* for 10 min. This pellet was resuspended in 1/5 volume of sterile H₂O and mechanically disrupted by douncing in a Dounce homogenator. Immediately after this treatment, sucrose was added to the homogenate to a final concentration of 250 mM. Unsolubilized material was removed by centrifugation. Cleared lysate was incubated for 3 h at 4°C under rotary shaking with the immobilized mAb MCP 21 as a batch preparation. The material was then loaded onto a column and washed extensively with 20 mM Tris-HCl (pH 7.6), and 50 mM NaCl to remove unattached material. 20S proteasome was eluted with 20 mM Tris-HCl (pH 7.6) and 2 M NaCl. The eluate was dialyzed for 24 h at 4°C against 20 mM Tris-HCl (pH 7.6) and concentrated to 4 mg/ml. The average yield was ~1 mg purified proteasome/150 ml blood. Homogeneity of the eluted material was confirmed by analysis of an aliquot by SDS-12% PAGE and Coomassie blue staining of the gel.

Enzymatic Assays. The activity of the proteasome was assayed using the following fluorogenic peptides: Z-Gly-Gly-Arg- β NA (Z-GGR- β NA; Z = benzyloxycarbonyl and β NA = β -naphthylamide) for tryptic-like activity, Z-Leu-Leu-Glu- β NA (Z-LLE- β NA) for PGPH activity, and Suc-Leu-Leu-Val-Tyr-AMC

(Suc-LLVY-AMC; Suc = succinyl, and AMC = 7-amido-4-methylcoumarin) for chymotryptic-like activity. All peptides were purchased from Bachem. Each degradation assay contained 5 μ g proteasome plus 100 μ M peptides Z-GGR- β NA and Z-LLE- β NA or 10 μ M Suc-LLVY-AMC in a final volume of 100 μ l. The reaction was incubated at 25°C for 20 min, at which time the reaction was quenched with cold 100% ethanol. Fluorescence emission was measured using a Perkin Elmer fluorometer. Fluorescence excitation/emission wavelengths were 335:410 nm for β NA and 380:440 nm for AMC. Where indicated, the proteasome inhibitor lactacystin (Biomol) was incubated for 15 min with proteasome at 25°C before the addition of the peptide substrates. The final concentration of lactacystin was 50 μ M.

Peptide Synthesis. Peptides were synthesized using standard solid-phase F-moc chemistry on an Applied Biosystems synthesizer. After side chain deprotection and release from the resin, the peptides were purified by reverse-phase preparative HPLC using a Vydac C18 column. Fractions containing the expected product, as judged by mass spectrometry, were pooled and lyophilized. The purified material was then subjected to matrix assisted laser desorption ionization-time of flight (MALDI-TOF) and analytical HPLC analysis. All peptides were >95% pure as indicated by analytical HPLC.

Peptide Digestion and Mass Spectrometry. For analysis by mass spectrometry, 4 nmol peptide was incubated for 40 min at 37°C with 16 μ g purified proteasome in a final volume of 10 μ l. Where indicated, lactacystin was added to a final concentration of 50 μ M. The samples containing proteasome and lactacystin were incubated for 15 min at 37°C before the addition of peptide. The reaction was terminated by the addition of 5% TFA and immediate immersion in liquid N₂. The samples were subsequently lyophilized. The lyophilized samples were dissolved in 20 μ l 1% TFA/H₂O. An aliquot of this solution (1.5 μ l) was mixed with 24 μ l of matrix solution (5 mg/ml α -cyano-4-hydroxyl-cinnamic acid; Sigma Chemical Co.) in 1% TFA/H₂O:acetonitrile (1:1, vol/vol) and 1 μ l of this mixture was deposited on a gold plated target and vacuum dried before transferring it into the source of the mass spectrometer.

MALDI mass spectra were obtained on a Perseptive Biosystems Voyager RP spectrometer using a 337-nm nitrogen laser, a 25-kV accelerating potential, and a delayed extraction of 150 ns. Each spectrum was the result of an accumulation of 128 single laser shots. External calibration of the MALDI spectra in the linear mode was carried out using a low molecular weight standard (Perseptive Biosystems). The mass determination was based on the mass-to-charge (m/z) ratio. The instrument error ranges between 0.01 and 0.1% of the molecular mass.

Peptide Digestion and ⁵¹Cr Release Assay. Samples used in subsequent CTL assay included 100 pmol peptide and 4 μ g purified proteasome. Where indicated, trypsin (1 mg/ml) was added to the peptide and incubated for 20 min at 37°C in 10 mM Tris-HCl, pH 8.0. The reaction performed was identical to the reaction for the mass spectrometry analysis. Target cells were labeled with ⁵¹Cr for 1 h at 37°C and washed twice. Labeled target cells (1,000 cells in 50 μ l RPMI medium/5% FCS) were added to serial dilutions of the various peptide preparations (100 μ l) in v-bottomed microwells for 15 min at room temperature. The CTL were then added at the appropriate E/T in 50 μ l RPMI medium/5% FCS, and the release of ⁵¹Cr was measured after incubation for 4 h at 37°C. Specific lysis was calculated as follows:

$$\% \text{ specific lysis} = \left[\frac{(\text{Experimental release} - \text{spontaneous release})}{(\text{Total release} - \text{spontaneous release})} \right] \times 100.$$

Infection with Recombinant Vaccinia Virus and Treatment of Cells with Proteasome Inhibitors. Approximately 10⁶ LCL721.45 cells (25) were treated with 100 μ M lactacystin for 1 h, washed, and incubated overnight in 1 μ M lactacystin at 37°C. Cells were then infected with recombinant vaccinia virus (rec. v.v.) expressing the MAGE-3₁₋₃₁₄ protein at a multiplicity of infection of 10 and simultaneously labeled with 100 μ Ci of ⁵¹Cr for 2 h. The cells were washed and incubated at 37°C for another 4 h before being exposed to the MAGE-3-specific CTL clone 3C5 at the E/T indicated in Fig. 7. Rec. v.v. encoding the MAGE-3 protein was generated by recombination with a pSc11 derivative plasmid as described previously (26). The cDNA coding for MAGE-3 was digested with PstI and XbaI, blunted using Klenow PolI, and inserted into the SmaI site of the vector pSc11.

The HLA-A*0201⁺ MAGE-3⁺ melanoma cell line SK23-MEL (18) was treated with 10 μ M lactacystin or 100 μ M LLnL for 17 h. Subsequently, 10⁶ cells were labeled with 100 μ Ci of ⁵¹Cr for 2 h, washed, and incubated with the MAGE-3-specific CTL clone 3C5 for 8 h at 37°C.

Results

Experimental Strategy. We have previously derived a MAGE-3₂₇₁₋₂₇₉-specific CTL line from PBL of a melanoma patient that, although able to readily recognize HLA-A*0201⁺ cells exposed to exogenously added synthetic MAGE-3₂₇₁₋₂₇₉ peptide, was unable to lyse cells expressing the MAGE-3 protein (18). To address this discrepancy, we assessed in the present study the recognition of HLA-A*0201⁺ melanoma cells transfected with cDNA or cDNA fragments encoding the MAGE-3 protein. Expression of the various MAGE-3 gene products in transfected cells was determined by the UPR technique, originally developed to increase the accuracy of protein decay measurements (20).

Ub is a highly conserved protein that, in many instances, serves as a proteasomal degradation signal by forming a multiubiquitin chain on lysine residue(s) of a protein (27). Ub is naturally synthesized as a fused protein—either to itself or to other cellular proteins—and is rapidly cleaved by a member of the Ub-specific proteases. The UPR technique exploits this natural linear arrangement of the Ub gene and relies on a linear fusion with Ub located between a reference protein (here GFP) and a protein of interest (Fig. 1). The rapid cleavage of the fusion protein by Ub-specific proteases after the last residue of Ub yields equimolar amounts of the protein of interest and the reference protein bearing a COOH-terminal Ub moiety. It is noteworthy that the use of Ub fusion also enabled us to bypass the need for a methionine residue at the NH₂ termini of the MAGE-3 peptide fragments. Finally, a sequence encoding a peptide tag derived from the influenza ha was inserted between the GFP and Ub moieties to permit the detection and quantitation of GFP_{Pha}-Ub fusion.

NA8-MEL cells (HLA-A*0201⁺MAGE-3⁻) were transiently transfected with the plasmids pGFP/Ub-MAGE-3₁₋₃₁₄, pGFP/Ub-MAGE-3₂₇₁₋₂₇₉, pGFP/Ub-MAGE-3₂₅₆₋₂₇₉, or pGFP/Ub-MAGE-3₂₇₁₋₂₈₅ coding for the reference GFP_{Pha}-Ub and either MAGE-3₁₋₃₁₄, MAGE-3₂₇₁₋₂₇₉, MAGE-3₂₅₆₋₂₇₉, or MAGE-3₂₇₁₋₂₈₅, respectively (Fig. 1, constructs

I–IV). The transfected cells were labeled with [³⁵S]methionine/cysteine for 60 min, lysed, immunoprecipitated using saturating amounts of monoclonal anti-ha antibody and monoclonal anti-MAGE-3 antibody, and analyzed by SDS-PAGE and autoradiography. The radioactive band corresponding to the reference GFP_{Pha}-Ub could be detected in all lanes where cells had been transfected with UPR-based plasmids (Fig. 2, lanes a–d) but not in mock-transfected cells (lane e). The protein MAGE-3 was only detected in cells transfected with the full length MAGE-3 gene (lane a) and migrated as a doublet. The upper band of the doublet is the result of a posttranslational modification other than phosphorylation or N-glycosylation (data not shown). The presence of the reference protein in the other lanes confirmed the expression of the MAGE-3 protein fragments. Using the GFP-based UPR technique, we estimated that the transiently transfected constructs were expressed in ~2% of the melanoma cells (data not shown).

CTL Recognition of Cells Expressing MAGE-3₁₋₃₁₄, MAGE-3₂₇₁₋₂₇₉, and MAGE-3₂₇₁₋₂₇₉ Extended Precursors. NA8-MEL cells transfected with pGFP/Ub-MAGE-3₁₋₃₁₄ (Fig. 1, construct I) and pGFP/Ub-MAGE-3₂₇₁₋₂₇₉ (construct II) encoding the reference protein GFP_{Pha}-Ub and either MAGE-3₁₋₃₁₄ or MAGE-3₂₇₁₋₂₇₉, respectively, were incubated with cells from the CTL line specific for MAGE-3₂₇₁₋₂₇₉ at a lymphocyte-to-target cell ratio of 30:1. After 24 h of coculture, supernatants were assayed for the presence of TNF-α released by activated CTL. The amount of TNF-α produced by CTL incubated with cells expressing MAGE-3₁₋₃₁₄ was not significantly higher than that produced by CTL incubated with mock-transfected cells (Fig. 3). In contrast, cells expressing MAGE-3₂₇₁₋₂₇₉ were efficiently recognized by CTL as indicated by the 50-fold increase in the amount of TNF-α produced. As expected, addition of a saturating amount of the corresponding MAGE-3₂₇₁₋₂₇₉ synthetic peptide to mock-transfected cells resulted in a strong production of TNF-α. Therefore, the impaired presentation of MAGE-3₂₇₁₋₂₇₉ by NA8-MEL cells transfected with MAGE-3₁₋₃₁₄ was not caused by an inefficient transport or loading of the peptide on HLA-A*0201 molecules but rather by an inaccurate processing of the protein MAGE-3.

To locate the region of the protein affecting the generation of the antigenic peptide, we extended the sequence of




Figure 2. The use of UPR technique in assessing the expression of transfected plasmids. NA8-MEL cells were transiently transfected with plasmids pGFP/Ub-MAGE-3₁₋₃₁₄ (lane a),

pGFP/Ub-MAGE-3₂₇₁₋₂₇₉ (lane b), pGFP/Ub-MAGE-3₂₅₆₋₂₇₉ (lane c), pGFP/Ub-MAGE-3₂₇₁₋₂₈₅ (lane d), or mock transfected (lane e). Transfected cells were metabolically labeled with [³⁵S]methionine/cysteine, followed by immunoprecipitation and SDS-PAGE analysis. The band corresponding to the reference GFP_{Pha}-Ub is indicated on the left. In lane a, the protein MAGE-3₁₋₃₁₄ detected by a monoclonal antibody raised against MAGE-3 migrates as a doublet. The upper band of the doublet is the result of a posttranslational modification. The band corresponding to GFP_{Pha}-Ub is absent in mock-transfected cells (lane e).




Figure 3. Recognition of transfected NA8-MEL cells by CTL specific for HLA-A*0201-restricted MAGE-3₂₇₁₋₂₇₉. Cells transfected with the plasmids pGFP/Ub-MAGE-3₁₋₃₁₄, pGFP/Ub-MAGE-3₂₇₁₋₂₇₉, pGFP/Ub-MAGE-3₂₅₆₋₂₇₉, and pGFP/Ub-MAGE-3₂₇₁₋₂₈₅ were cocultured for 24 h with CTL at a lymphocyte to target cell ratio of 30:1. The production of TNF-α was measured by testing the toxicity of the culture supernatant on TNF-sensitive cells. The amount of TNF-α produced by cells expressing MAGE-3₁₋₃₁₄ or MAGE-3₂₇₁₋₂₈₅ corresponds to 4 pg/ml and is not significantly different from mock-transfected cells (solid black bar). Cells expressing MAGE-3₂₇₁₋₂₇₉ or MAGE-3₂₅₆₋₂₇₉ induced a 50-fold increase in the production of TNF-α. NA8-MEL cells exposed to 1 μg/ml exogenous MAGE-3₂₇₁₋₂₇₉ peptide (white bar) were efficiently recognized by the CTL.

MAGE-3₂₇₁₋₂₇₉ at the NH₂ terminus by 15 amino acids (Fig. 1, construct III) and at the COOH terminus by 6 amino acids (construct IV). NA8-MEL cells were transfected with the plasmids coding for GFP_{Pha}-Ub and either MAGE-3₂₅₆₋₂₇₉ or MAGE-3₂₇₁₋₂₈₅, respectively. Cells expressing the fragment MAGE-3₂₅₆₋₂₇₉ were well recognized by CTL (Fig. 3). On the contrary, cells transfected with the plasmid encoding MAGE-3₂₇₁₋₂₈₅ were not recognized by CTL. The length of the COOH-terminal extension did not influence the recognition of the transfected cells, as cells expressing MAGE-3₂₇₁₋₂₇₉ with a COOH-terminal extension of 15 amino acids did not lead to a recognition of the cells, either (data not shown). Therefore, the processing protease was unable to generate the MAGE-3₂₇₁₋₂₇₉ peptide from a COOH-terminally extended precursor but could generate it from a precursor containing a preprocessed COOH terminus as the result of genetic engineering.

Analysis of Peptide Fragments Generated after Digestion with Purified Proteasome In Vitro. The human proteasome has been implicated in the generation of antigenic peptides presented by HLA class I molecules to CTL (11–13). We tested whether the peptide fragments obtained after exposure of NH₂- and COOH-terminally extended MAGE-3₂₇₁₋₂₇₉ precursors to purified human proteasome correlated with the results obtained using transfected cells. Synthetic peptide MAGE-3₂₇₁₋₂₈₅ was incubated for 40 min at 37°C in the presence of proteasome purified from blood and was subsequently analyzed by mass spectrometry (Fig. 1 B and Fig. 4, A and B). A major peak corresponding to the original peptide MAGE-3₂₇₁₋₂₈₅ (theoretical mass 1,766 daltons) was detectable at time 0. Several additional peaks of lower mass appeared after incubation with the proteasome. These




Figure 4. Fragments generated after digestion of synthetic peptides with purified proteasome *in vitro*. The synthetic peptide MAGE-3₂₇₁₋₂₈₅ (A–C) corresponding to a COOH-terminal extension of the antigenic peptide MAGE-3₂₇₁₋₂₇₉ or MAGE-3₂₅₆₋₂₇₉ (D–F) corresponding to an NH₂-terminal extension of the antigenic peptide were incubated for 0 (A and D) or 40 min (B and E) at 37°C with 15 μg proteasome purified from human blood. A 40-min digestion was also performed in the presence of 50 μM lactacystin (C and F). The samples were then analyzed by mass spectrometry. The identity of the detected peaks was determined based on the specific mass of each peptide fragment and is denoted by the position of the fragment within the precursor peptide sequence. Note the presence of a peak corresponding to the antigenic peptide MAGE-3₂₇₁₋₂₇₉ in C, E, and F. The sequences of the precursor peptides are indicated, in one-letter code, at the top and the antigenic 9-mer is underlined. Contaminating peaks are not labeled.

degradation products were unambiguously identified as the 11-mer MAGE-3₂₇₁₋₂₈₁ (1,288 daltons), the 10-mer MAGE-3₂₇₁₋₂₈₀ (1,187 daltons), the 8-mer MAGE-3₂₇₁₋₂₇₈ (959 daltons) and the 7-mer MAGE-3₂₇₂₋₂₇₈ (812 daltons). No peak corresponding to the 9-mer MAGE-3₂₇₁₋₂₇₉ (1,058 daltons) was detected.

A similar analysis was performed using peptide MAGE-3₂₅₆₋₂₇₉ (Fig. 1 B). The major peak detected at time 0 corresponded to the original peptide (2,767 daltons; Fig. 4 D). After incubation with proteasome, the 9-mer corresponding to MAGE-3₂₇₁₋₂₇₉ (1,058 daltons) was clearly detected (Fig. 4 E). Moreover, several other peaks were detected and identified as the 10-mer MAGE-3₂₅₆₋₂₆₅ (1,163 daltons), the 8-mer MAGE-3₂₇₂₋₂₇₉ (911 daltons), and the 7-mer MAGE-3₂₇₂₋₂₇₈ (812 daltons). The relative signal intensity of peptide MAGE-3₂₅₆₋₂₇₉ was reproducibly lower than that of peptide MAGE-3₂₇₁₋₂₈₅ and may reflect the chemical properties of this peptide. Thus, results obtained with *in vitro* digestion of synthetic MAGE-3 peptide extensions not only confirmed the results obtained with DNA-encoded peptides expressed intracellularly but also enabled precise identification of the degradation products.

Selective Inhibition of Proteasomal Activity *In Vitro* Influences the Production of Peptide MAGE-3₂₇₁₋₂₇₉. To ascertain the role of the different enzymatic activities of the proteasome in the generation of the proteolytic fragments *in vitro*, we performed experiments similar to the one described above in the presence of lactacystin, a specific inhibitor of the proteasome. Lactacystin has been shown to irreversibly block the trypsin-like and chymotrypsin-like activities, re-

versibly inhibit the PGPH activity, and moderately block the BrAAP activity of the proteasome (28, 29).

Purified MAGE-3₂₅₆₋₂₇₉ and MAGE-3₂₇₁₋₂₈₅ peptides were incubated for 40 min in the presence of proteasome and 50 μM lactacystin and analyzed by mass spectrometry (Fig. 4, C and F). Digestion of peptide MAGE-3₂₇₁₋₂₈₅ (C) resulted in the appearance of several peaks with masses similar to those obtained after the digestion without lactacystin (compare with B). Unexpectedly, the peptide species corresponding to the 9-mer MAGE-3₂₇₁₋₂₇₉ (1,058 daltons) was generated to a detectable level. The peak corresponding to the 7-mer MAGE-3₂₇₂₋₂₇₈ (812 daltons) was not detectable in the sample incubated with the proteasome inhibitor. Digestion of peptide MAGE-3₂₅₆₋₂₇₉ in the presence of lactacystin (F) yielded new peaks corresponding to the 12-mer MAGE-3₂₅₆₋₂₆₇ (1,331 daltons) and the 6-mer MAGE-3₂₅₆₋₂₆₁ (807 daltons), in addition to the 9-mer MAGE-3₂₇₁₋₂₇₉ (1,058 daltons) and the 8-mer MAGE-3₂₇₂₋₂₇₉ (912 daltons) already detected in digestion without lactacystin (E). It is interesting to note that the relative intensity of the peak corresponding to the antigenic 9-mer was reproducibly higher in digestions containing lactacystin than in those performed in the absence of lactacystin (compare E and F).

Lactacystin Inhibits Two of the Three Tested Proteasomal Activities. To identify the lactacystin-mediated effect on the enzymatic activity of the proteasome, we performed a digestion of the fluorescent substrates Z-GGR-βNA (for trypsin-like activity), Z-LLE-βNA (for PGPH activity), and Suc-LLVY-AMC (for chymotrypsin-like activity) in

the presence or absence of 50 μM lactacystin (Fig. 5). Although all fluorescent substrates were cleaved by the proteasome in the absence of lactacystin as detected by increased fluorescence, two of the three activities of the proteasome could be efficiently blocked by the addition of lactacystin. The PGPH activity was only marginally affected by the presence of lactacystin. Further purification of the proteasome by size chromatography did not alter this effect, ruling out the contribution of other low molecular weight proteases present in the purified preparation (data not shown).

Specific CTL Can Recognize Target Cells Pulsed after Digestion of Peptide Precursors. Since the generation of the 9-mer MAGE-3₂₇₁₋₂₇₉ from peptides MAGE-3₂₇₁₋₂₈₅ and MAGE-3₂₅₆₋₂₇₉ was enhanced in the presence of lactacystin, we tested whether the peptide generated under this condition was able to sensitize target cells for lysis by MAGE-3₂₇₁₋₂₇₉-specific CTL. Peptides MAGE-3₂₇₁₋₂₈₅ and MAGE-3₂₅₆₋₂₇₉ were either added directly to target cells or were first incubated with purified proteasome for 20 min at 37°C in the absence or presence of lactacystin. After 20 min, the reaction was stopped by the addition of 5% TFA and lyophilized. The lyophilized material was resuspended in medium and added in different dilutions to ⁵¹Cr-labeled

T2 cells. These HLA-A*0201⁺ cells are TAP deficient but can be efficiently sensitized with exogenous peptides for recognition by specific CTL.

Direct addition of the peptide MAGE-3₂₇₁₋₂₈₅ resulted in lysis of T2 cells only at very high peptide concentration (Fig. 6 A). This activity was probably caused by the presence of a small amount of peptide MAGE-3₂₇₁₋₂₈₀ produced by the hydrolysis of peptide MAGE-3₂₇₁₋₂₈₅. Indeed, the MAGE-3₂₇₁₋₂₇₉-specific CTL used in the present study was able to recognize the synthetic decapeptide MAGE-3₂₇₁₋₂₈₀ (50% maximal lysis at 100 nM), although much less efficiently than the 9-mer MAGE-3₂₇₁₋₂₇₉ (50% maximal lysis at 0.1 nM). No additional activity was observed after digestion of peptide MAGE-3₂₇₁₋₂₈₅ with proteasome for 20 min (Fig. 6 A). In contrast, incubation of peptide MAGE-3₂₇₁₋₂₈₅ with proteasome and lactacystin for 20 min resulted in the generation of an antigenic peptide recognized \sim 20-fold more efficiently by the MAGE-3₂₇₁₋₂₇₉-specific CTL (B). Based on the specificity of the CTL and on the degradation products detected by mass spectrometry, we concluded that the antigenic peptide MAGE-3₂₇₁₋₂₇₉ was indeed produced in the presence of lactacystin. Digestion of peptide MAGE-3₂₇₁₋₂₈₅ with trypsin completely abrogated recognition of the target cells by specific CTL.




Figure 5. Proteolytic activity of purified proteasome in the absence or presence of proteasome inhibitors. The tryptic-like, PGPH, and chymotryptic-like activities of purified proteasome (5 μg) were tested using 100 μM Z-GGR- β NA (black bar), 100 μM Z-LLE- β NA (hatched bar), or 10 μM Suc-LLVY-AMC (gray bar), respectively. In samples containing the inhibitor lactacystin (50 μM), proteasome was incubated for 15 min at 25°C before the addition of the fluorogenic peptide substrate. The reaction was allowed to proceed for 20 min at 25°C. Peptide hydrolysis was detected by monitoring the increased fluorescence in arbitrary units (A.U.) emitted by the released fluorogenic group β NA (excitation/emission of 335:410 nm) or AMC (excitation/emission of 380:440 nm). In the absence of proteasome (–), only background activity is detected. A representative plot is depicted here. Identical results were obtained using three independent proteasome preparations and two different lots of lactacystin.




Figure 6. Lysis of T2 target cells pulsed with proteasome-digested peptide products by MAGE-3₂₇₁₋₂₇₉-specific CTL. Precursors corresponding to MAGE-3₂₇₁₋₂₈₅ (A and B) or MAGE-3₂₅₆₋₂₇₉ (C and D) were incubated with proteasome for 0 or 20 min at 37°C in the absence (A and C) or presence (B and D) of 50 μM lactacystin. In each condition, the precursor was also digested with trypsin or maintained in the absence of proteasome. Upon completion of the incubation, the samples were lyophilized, resuspended in medium, and added in fivefold dilution steps to ⁵¹Cr-labeled T2 cells. Cr release was measured after 4 h. The half-maximal lysis of cells pulsed with a saturating amount of the antigenic MAGE-3₂₇₁₋₂₇₉ peptide was 0.01 nM (not shown).

A similar assay was performed using peptide MAGE-3₂₅₆₋₂₇₉ as substrate. Again, direct addition of the peptide precursor produced low but detectable lytic activity at high concentration. Digestion of the extended peptide for 20 min in the absence of lactacystin led to a 10-fold increase in lytic activity (Fig. 6 C), an effect compatible with the detection of peptide MAGE-3₂₇₁₋₂₇₉ in the digestion products analyzed by mass spectrometry (Fig. 4 E). This activity was completely abolished by the addition of trypsin. However, digestion of peptide MAGE-3₂₅₆₋₂₇₉ in the presence of 50 μ M lactacystin resulted in 100-fold-increased recognition (Fig. 6 D). This effect was most likely caused by the increased amount of MAGE-3₂₇₁₋₂₇₉ generated after proteasomal digestion in the presence of lactacystin as suggested by the increased relative intensity of the MAGE-3₂₇₁₋₂₇₉ peak detected by mass spectrometry (Fig. 4 F).

Treatment of Cells Expressing MAGE-3₁₋₃₁₄ with Proteasome Inhibitors Results in Efficient Presentation of MAGE-3₂₇₁₋₂₇₉. To ascertain the relevance of the positive effect of lactacystin on the generation of peptide MAGE-3₂₇₁₋₂₇₉ by the proteasome, we infected HLA-A*0201⁺ lymphoblastoid cells with rec. v.v. coding for MAGE-3₁₋₃₁₄ (Fig. 7 A). Infected cells expressing the full length protein MAGE-3₁₋₃₁₄ were not efficiently recognized by MAGE-3₂₇₁₋₂₇₉-specific CTL. However, treatment of the same cells with lactacystin prior to and during the infection lead to the efficient lysis of the infected cells. To determine whether the lactacystin-mediated effect observed in lymphoblastoid cells upon infection and high level expression of MAGE-3 could also be observed in uninfected melanoma cells, lysis of HLA-A*0201⁺MAGE-3⁺ melanoma cells was measured after treatment with lactacystin. As expected, lysis of untreated target cells was very low (Fig. 7 B). In contrast, treatment with lactacystin led to efficient lysis of the melanoma cells. A similar effect was also observed after treatment of the target cells with the calpain (and proteasome) inhibitor I LLnL. Taken together, these results strongly support the findings obtained after in vitro digestion of peptide precursors by purified proteasome and lead us to conclude that the generation and presentation of peptide MAGE-3₂₇₁₋₂₇₉

detected after treatment with lactacystin is a direct consequence of the partial inhibition of the proteasome in cells.

Discussion

Two major findings are reported in this work: First, melanoma cells transfected with cDNA encoding either the preprocessed antigenic peptide MAGE-3₂₇₁₋₂₇₉ (FLWG-PRALV) or the same peptide with an NH₂-terminal extension were recognized by MAGE-3₂₇₁₋₂₇₉-specific CTL. In contrast, melanoma cells expressing the full length protein MAGE-3₁₋₃₁₄ or peptide MAGE-3₂₇₁₋₂₇₉ with a COOH-terminal extension were not recognized. This discrepancy stems from the inappropriate proteasomal cleavage at the COOH terminus of the antigenic peptide. Second, treatment of MAGE-3⁺ melanoma cells with lactacystin resulted in the recognition of these normally unrecognized cells by MAGE-3₂₇₁₋₂₇₉-specific CTL. This effect strongly correlates with the partial inhibition of proteasomal activity in vitro and the lactacystin-induced generation of peptide MAGE-3₂₇₁₋₂₇₉ from the COOH-terminally extended precursor.

Expression of a minigene product in transfected cells has been difficult to assess by means other than functional assays. However, use of the UPR technique in this study not only allowed us to confirm the presence of the various minigene products via the detection of the reference protein GFP-Ub but also to quantitate the various MAGE-3 gene products, as both the reference protein GFP-Ub and the MAGE-3 protein, or protein fragments, were produced in equimolar amounts. Thus, the observed differences in CTL recognition of target cells transfected with the minigene encoding peptide MAGE-3₂₇₁₋₂₇₉ or the full length protein MAGE-3₁₋₃₁₄ could not be attributed to different expression levels of the two products but rather to the generation, or lack thereof, of the antigenic peptide. Cells expressing a short-lived variant of the MAGE-3₁₋₃₁₄ protein were not recognized by specific CTL, either (data not shown), eliminating the possibility that the lack of recognition was caused by a slow degradation of the MAGE-3




Figure 7. (A) Lactacystin restores the presentation of the MAGE-3₂₇₁₋₂₇₉ in cells expressing virally encoded MAGE-3. When left untreated, the HLA-A*0201⁺MAGE-3⁻ lymphoblastoid cell line LCL721.45 infected with rec. v.v. encoding MAGE-3 is not recognized by MAGE-3₂₇₁₋₂₇₉-specific CTL (rec. v.v.-MAGE3). Treatment of the infected cells with lactacystin prior to and during the infection renders them sensitive to the lysis by specific CTL (rec. v.v.-MAGE3 + lactacystin). (B) Effect of proteasome inhibitors on the presentation of peptide MAGE-3₂₇₁₋₂₇₉ in human melanoma cells. In contrast to the untreated HLA-A*0201⁺MAGE-3⁺ melanoma cell line SK23-MEL, treatment with either 10 μ M lactacystin or 100 μ M LLnL for 17 h enhances the presentation of peptide MAGE-3₂₇₁₋₂₇₉ to specific CTL. See Materials and Methods for details.

protein leading to a suboptimal concentration of the antigenic peptide. Finally, reciprocal transplantation of the MAGE-3₂₇₁₋₂₇₉ sequence into unrelated proteins indicated that the impaired generation of the antigenic peptide was not caused by residues flanking peptide MAGE-3₂₇₁₋₂₇₉ (data not shown). Altogether, these results suggested that the sequence of peptide MAGE-3₂₇₁₋₂₇₉ itself contributed to the improper processing of the MAGE-3 protein and led us to study the role of the proteasome in the deficient production of the antigenic peptide.

The involvement of the proteasome in the processing of antigenic peptides has been inferred from two sets of data: First, treatment of target cells with specific proteasome inhibitors abolished CTL-mediated recognition of antigenic peptides derived from intracellular proteins without affecting recognition of preprocessed endogenous or exogenous antigenic peptides (13). Second, analysis of proteasome-mediated degradation of synthetic peptide substrates *in vitro* revealed that the structural features of the digested products were compatible with those of peptides naturally associated with MHC class I molecules (30). However, several reports have recently demonstrated that the presentation of certain antigenic peptides, derived mostly from protein fragments, were insensitive to the effects of proteasome inhibitors (28, 31, 32). Moreover, cell surface expression of assembled MHC class I proteins in cells lacking proteasomal function suggests that other proteases may be involved in the generation of antigenic peptides (33). Therefore, the participation of two complementary and possibly overlapping proteolytic systems in antigen processing could be envisaged and would be compatible with our results obtained after treatment of melanoma cells with lactacystin. To address this question in greater detail, we isolated human proteasome and performed *in vitro* digestion studies using synthetic peptides. After digestion, the samples were immediately analyzed by mass spectrometry so as to uncover all possible fragments generated by the proteasome. Using this approach, we obtained strong evidence in favor of the involvement of the proteasome in the final proteolytic step leading to the generation of the antigenic peptide MAGE-3₂₇₁₋₂₇₉, notwithstanding the possibility that distinct cellular proteases may be involved at other stages in the processing of the MAGE-3 protein into precursor peptide fragments.

Five proteolytic activities of the proteasome have been described using short synthetic fluorogenic peptides: a tryptic-like activity, a chymotryptic-like activity, a PGPH activity, a BrAAP activity, and a SNAAP activity (3). Lactacystin has been shown to irreversibly block the trypsin-like and chymotrypsin-like activities and only partially block the PGPH and the BrAAP activities (28, 29, 34). No information is available on the inhibition of the SNAAP activity by lactacystin. In agreement with these results, we also found that the proteasome inhibitor lactacystin did not completely abrogate certain proteasomal activities but resulted in an altered degradation of synthetic peptides. Although previous results indicated that I LLnL blocks all five activities, recent reports have shown only selective inhibition of the chymotryptic-like activity (10, 13, 34).

In the presence of lactacystin, the degradation of MAGE-3 peptide precursors by purified proteasome was only partially and selectively inhibited, even if the tryptic and chymotryptic activities on short fluorogenic peptides were completely abrogated (Figs. 4 and 5). Indeed, we could still detect fragments generated by cleavage after leucine, valine, glutamic acid, alanine, and threonine. Therefore, we envisage two possibilities: First, the remaining PGPH activity not only cleaves at the COOH terminus of glutamic acid but may be more permissive and also cleave after nonacidic amino acid residues, or, second, the catalytic subunits responsible for the BrAAP and SNAAP activities of the proteasome, in addition to those responsible for the PGPH activity, are not affected by lactacystin. In light of recent results obtained after the analysis of peptide fragments generated by purified yeast proteasome (34), we favor the first hypothesis and suggest that the functionally defined PGPH activity is mediated by the same catalytic subunit as are the SNAAP and/or BrAAP activities. It is noteworthy that, in some cases, the PGPH activity of mammalian proteasome has been shown to result in cleavage after aromatic amino acids (35).

Close comparison of the fragments detected by mass spectrometry in the absence or presence of lactacystin suggests that, in the case of peptide MAGE-3₂₇₁₋₂₈₅, the antigenic fragment MAGE-3₂₇₁₋₂₇₉ is only detected in the absence of the fragment MAGE-3₂₇₂₋₂₇₈. The production of the latter appears to be inhibited by lactacystin. Assuming the presence of two competing proteolytic activities of the proteasome, one dominant under normal conditions and producing peptide MAGE-3₂₇₂₋₂₇₈ and the other resulting in peptide MAGE-3₂₇₁₋₂₇₉, it is possible that the inhibition of the dominant activity by lactacystin favors the lactacystin-insensitive activity, yielding only the antigenic peptide MAGE-3₂₇₁₋₂₇₉. Alternatively, the positioning of the peptide in the inner cavity of the proteasome may favor the cleavage, generating peptide MAGE-3₂₇₂₋₂₇₈ under normal conditions. The covalent binding of lactacystin to the subunit responsible for the chymotryptic activity (29) may reorient the peptide substrate in the cavity and lead to the generation of peptide MAGE-3₂₇₁₋₂₇₉.

It has been reported that antigenic peptides from the same protein may be processed with different efficiencies (36, 37). In this context, it is noteworthy that the protein MAGE-3 contains, in addition to the poorly presented peptide studied here, other antigenic peptides which are well presented by MAGE-3⁺ melanoma cells in association with HLA-A1 or HLA-B44 molecules (15, 16). In a survey of antigenic peptides carrying the motif Ala-Leu-Val present at the COOH terminus of peptide MAGE-3₂₇₁₋₂₇₉, we identified two such peptides. The first one, derived from the influenza nucleoprotein NP₁₄₇₋₁₅₅ (H-2 K^d-restricted), has been shown to be inefficiently produced in H-2 K^d-positive infected cells (~30 peptides/cell) in comparison to another antigenic peptide NP₅₀₋₅₇ (1,800 peptides/cell; 36). Interestingly, recent results have indicated that the presentation of peptide NP₁₄₇₋₁₅₅ in infected cells was enhanced by the addition of lactacystin (38). Although it has been

shown that amino acids at position 156 could positively influence the generation of the antigenic peptide NP₁₄₇₋₁₅₅ (39), we did not observe any effect of the amino acid at the COOH terminus of the cleavage site of peptide MAGE-3₂₇₁₋₂₇₉. Indeed, transplantation of the MAGE-3₂₇₁₋₂₇₉ sequence into two unrelated proteins (carrying either the residue histidine or isoleucine immediately after the COOH-terminal valine) did not result in the presentation of peptide MAGE-3₂₇₁₋₂₇₉ (data not shown). The second peptide is derived from the melanosomal TRP-2 protein (TRP-2₄₇₆₋₄₈₄, HLA-A*0201-restricted). Preliminary results suggest that this peptide is not presented by cells expressing TRP-2 but is efficiently presented when expressed as a minigene (Noppen, C., G. Spagnoli, and F. Lévy, unpublished results). All of these observations can be explained by the presence of unfavorable amino acids surrounding the cleavage site and acting as "negative processing signals." Elucidation of the exact nature of the postulated negative processing signal and determination of other putative signals is underway and should further refine the current pre-

dition algorithms used to select potential antigenic peptides. More importantly, understanding the proteolytic machinery controlling the generation and presentation of tumor-specific antigenic peptides in tumor cells should facilitate the development of efficient peptide-based vaccines aimed at inducing or enhancing the generation of tumor-reactive CTL in cancer patients. In parallel, demonstration that proteasome inhibitors like lactacystin or LLnL lead to the recognition of a peptide tumor antigen by specific CTL in melanoma cells opens the way to the development of specific proteasome inhibitors able to induce the presentation of antigens recognized by CTL and, hence, broaden the spectrum of CTL-defined tumor antigenic peptides to be considered for cancer vaccines. In this respect, the recent demonstration that the drug ritonavir, originally described as an inhibitor of HIV-1 protease and administered to HIV-1-infected patients, can act as proteasome inhibitor suggests that this drug may also favor the generation of new peptide tumor antigens efficiently recognized by specific CTL (40).

The expert technical assistance of A.-L. Peitrequin, A. Porret, and N. Montandon is gratefully acknowledged. We thank Dr. I. Miconnet and L. Burri for comments on the manuscript.

U. Gileadi, P.R. Dunbar, and V. Cerundolo were supported by the Medical Research Council of the United Kingdom and the Cancer Research Campaign. F. Lévy was supported in part by a grant from the Swiss Cancer League. This work was partly supported by the Federal Office for Education and Science, Switzerland and the European Community (contract BMH4-CT95-1627).

Address correspondence to Frédéric Lévy, Ludwig Institute for Cancer Research, Ch. des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41-21-692-59-98. Fax: 41-21-653-44-74. E-mail: frederic.levy@isrec.unil.ch

Received for publication 19 June 1998 and in revised form 15 December 1998.

References

1. Rivett, A.J. 1998. Intracellular distribution of proteasomes. *Curr. Opin. Immunol.* 10:110-114.
2. Baumeister, W., J. Walz, F. Zühl, and E. Seemüller. 1998. The proteasome: paradigm of a self-compartmentalized protease. *Cell.* 92:367-380.
3. Coux, O., K. Tanaka, and A.L. Goldberg. 1996. Structure and functions of the 20S and 26S proteasomes. *Annu. Rev. Biochem.* 65:801-847.
4. Ping, M.C., J.H. Vu, R.J. Proske, C.A. Slaughter, and G.N. DeMartino. 1994. Identification, purification and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20S proteasome. *J. Biol. Chem.* 269:3539-3547.
5. Ping, M.C., C.A. Slaughter, and G.N. DeMartino. 1992. Identification, purification and characterization of a protein activator (PA28) of the 20S proteasome (macropain). *J. Biol. Chem.* 267:10515-10523.
6. Dubiel, W., G. Pratt, K. Ferrell, and M. Rechsteiner. 1992. Purification of an 11S regulator of the multicatalytic protease. *J. Biol. Chem.* 267:22369-22377.
7. Dick, T.P., T. Ruppert, M. Groettrup, P.M. Kloetzel, L. Kuehn, U.H. Koszinowski, S. Stevanovic, H. Schild, and H.-G. Rammensee. 1996. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. *Cell.* 86:253-262.
8. Groll, M., L. Ditzel, J. Löwe, D. Stock, M. Bochtler, H.D. Bartunik, and R. Huber. 1997. Structure of 20S proteasome from yeast at 2.4 Å resolution. *Nature.* 386:463-471.
9. Kopp, F., K.B. Hendil, B. Dahlmann, P. Kristensen, A. Sobek, and W. Uerkvitz. 1997. Subunit arrangement in the human 20S proteasome. *Proc. Natl. Acad. Sci. USA.* 94:2939-2944.
10. Orłowski, M., C. Cardozo, and C. Michaud. 1993. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. *Biochemistry.* 32:1563-1572.
11. Svensson, K., F. Lévy, U. Sundberg, H.-G. Boman, K.B. Hendil, and S. Kvist. 1996. Proteasomes generate in vitro a natural peptide of influenza-A nucleoprotein functional in HLA-B27 antigen assembly. *Int. Immunol.* 8:467-478.

12. Groettrup, M., A. Soza, U. Kuckelkorn, and P.M. Kloetzel. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. *Immunol. Today*. 17:429–435.
13. Rock, K.L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell*. 78:761–771.
14. Pamer, E., and P. Cresswell. 1998. Mechanisms of MHC class I-restricted antigen processing. *Annu. Rev. Immunol.* 16: 323–358.
15. Herman, J., P. van der Bruggen, I.F. Luescher, S. Mandruzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P. Coulie. 1996. A peptide encoded by the human *MAGE3* gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing *MAGE3*. *Immunogenetics*. 43:377–383.
16. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene *MAGE-3* codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. *J. Exp. Med.* 179:921–930.
17. van der Bruggen, P., J. Bastin, T. Gajewski, P.G. Coulie, P. Boel, C. De Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by human gene *MAGE-3* and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing *MAGE-3*. *Eur. J. Immunol.* 24:3038–3043.
18. Valmori, D., D. Liénard, G. Waanders, D. Rimoldi, J.-C. Cerottini, and P. Romero. 1997. Analysis of *MAGE-3*-specific cytolytic T lymphocytes in human leukocytes antigen-A2 melanoma patients. *Cancer Res.* 57:735–741.
19. Dunbar, P.R., G.S. Ogg, J. Chen, N. Rust, P. van der Bruggen, and V. Cerundolo. 1998. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. *Curr. Biol.* 8:413–416.
20. Lévy, F., N. Johnsson, T. Rümenapf, and A. Varshavsky. 1996. Using ubiquitin to follow the metabolic fate of a protein. *Proc. Natl. Acad. Sci. USA.* 93:4907–4912.
21. Kocher, T., E. Schultz-Thater, F. Gudat, C. Schaefer, G. Casorati, A. Juretic, T. Willmann, F. Harder, M. Heberer, and G.C. Spagnoli. 1995. Identification and intracellular location of *MAGE-3* gene product. *Cancer Res.* 55:2236–2239.
22. Espevik, T., and J. Nissen-Meyer. 1986. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. *J. Immunol. Methods.* 95:99–105.
23. Hansen, M.B., S.E. Nielsen, and K. Berg. 1989. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J. Immunol. Methods.* 119:203–210.
24. Ehring, B., T.H. Meyer, C. Eckerskorn, F. Lottspeich, and R. Tampé. 1996. Effects of major-histocompatibility-complex-encoded subunits on the peptidase and proteolytic activities of human 20S proteasomes. *Eur. J. Biochem.* 235:404–415.
25. DeMars, R., C.C. Chang, S. Shaw, P.J. Reitnauer, and P.M. Sondel. 1984. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. *Human Immunol.* 11:77–97.
26. Cerundolo, V., A. Kelly, T. Elliott, J. Trowsdale, and A. Townsend. 1995. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. *Eur. J. Immunol.* 25:554–562.
27. Varshavsky, A. 1997. The ubiquitin system. *Trends. Biochem. Sci.* 22:383–387.
28. Vinitsky, A., L.C. Anton, H.L. Snyder, M. Orłowski, J.R. Bennink, and J.W. Yewdell. 1997. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors. *J. Immunol.* 159:554–564.
29. Fenteany, G., R.F. Standaert, W.S. Lane, S. Choi, E.J. Corey, and S.L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science.* 268:726–731.
30. Niedermann, G., G. King, S. Butz, U. Birsner, R. Grimm, J. Shabanowitz, D.F. Hunt, and K. Eichmann. 1996. The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides. *Proc. Natl. Acad. Sci. USA.* 93:8572–8577.
31. Craiu, A., T. Akopian, A. Goldberg, and K.L. Rock. 1997. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. *Proc. Natl. Acad. Sci. USA.* 94:10850–10855.
32. Lopez, D., and M. Del Val. 1997. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. *J. Immunol.* 159:5769–5772.
33. Glas, R., M. Bogoy, J.S. McMaster, M. Gaczynka, and H.L. Ploegh. 1998. A proteolytic system that compensates for loss of proteasome function. *Nature.* 392:618–622.
34. Dick, T.P., A.K. Nussbaum, M. Deeg, W. Heinemeyer, M. Groll, M. Schirle, W. Keilholz, S. Stevanovic, D.H. Wolf, R. Huber, et al. 1998. Contribution of proteasomal β -subunits to the cleavage of peptide substrates analyzed with yeast mutants. *J. Biol. Chem.* 273:25637–25646.
35. Wilk, S., M. Pereira, and B. Yu. 1991. Probing the specificity of the bovine pituitary multicatalytic proteinase complex by inhibitors, activators, and by chemical modification. *Biomed. Biochim. Acta.* 50:471–478.
36. Anton, L.C., J.W. Yewdell, and J.R. Bennink. 1997. MHC class I-associated peptides produced from endogenous gene products with vastly different efficiencies. *J. Immunol.* 158: 2535–2542.
37. Sijts, A.J., A. Neisig, J. Neeffjes, and E.G. Pamer. 1996. Two *Listeria monocytogenes* CTL epitopes are processed from the same antigen with different efficiencies. *J. Immunol.* 156: 685–692.
38. Anton, L.C., H.L. Snyder, J.R. Bennink, A. Vinitsky, M. Orłowski, A. Porgador, and J.W. Yewdell. 1998. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. *J. Immunol.* 160:4859–4868.
39. Yellen-Shaw, A.J., and L.C. Eisenlohr. 1997. Regulation of class I-restricted epitope processing by local or distal flanking sequence. *J. Immunol.* 158:1727–1733.
40. André, P., M. Groettrup, P. Klenerman, R. De Giuli, B.L. Booth, V. Cerundolo, M. Bonneville, F. Jotereau, R.M. Zinkernagel, and V. Lotteau. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. *Proc. Natl. Acad. Sci. USA.* 95:13120–13124.